WallStreetZenWallStreetZen

NASDAQ: ADPT
Adaptive Biotechnologies Corp Stock Forecast, Predictions & Price Target

Analyst price target for ADPT

Based on 5 analysts offering 12 month price targets for Adaptive Biotechnologies Corp.
Min Forecast
$8.00-18.78%
Avg Forecast
$16.60+68.53%
Max Forecast
$30.00+204.57%

Should I buy or sell ADPT stock?

Based on 5 analysts offering ratings for Adaptive Biotechnologies Corp.
Buy
Strong Buy
2 analysts 40%
Buy
1 analysts 20%
Hold
1 analysts 20%
Sell
1 analysts 20%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ADPT stock forecasts and price targets.

ADPT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
ScotiaBank
Top 21%
80
BuyInitiates Coverage On$15.00+52.28%2023-01-05
Piper Sandler
Top 22%
79
Strong BuyUpgrades$14.00+42.13%2022-12-21
Morgan Stanley
Bottom 5%
5
HoldMaintains$16.00+62.44%2022-11-07
Credit Suisse
Top 6%
95
SellInitiates Coverage On$8.00-18.78%2022-08-25
Anonymous
Goldman Sachs
HoldMaintains$10.00+1.52%2022-05-24
BTIG
Top 19%
82
Strong BuyMaintains$30.00+204.57%2022-02-16

1 of 1

Forecast return on equity

Is ADPT forecast to generate an efficient return?
Company
-30.19%
Industry
3.94%
Market
47.94%
ADPT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ADPT forecast to generate an efficient return on assets?
Company
-16.66%
Industry
1.79%
ADPT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ADPT earnings per share forecast

What is ADPT's earnings per share in the next 2 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$1.36
Avg 2 year Forecast
-$1.03

ADPT revenue forecast

What is ADPT's revenue in the next 2 years based on estimates from 5 analysts?
Avg 1 year Forecast
$223.2M+32.84%
Avg 2 year Forecast
$285.2M+69.75%
ADPT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADPT revenue growth forecast

How is ADPT forecast to perform vs Biotechnology companies and vs the US market?
Company
32.84%
Industry
301.54%
Market
70.6%
ADPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADPT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADPT$9.85$16.60+68.53%Buy
REPL$28.29$46.22+63.39%Strong Buy
TVTX$21.72$35.60+63.90%Buy
ACLX$32.70$36.00+10.09%Strong Buy
VERV$23.29$39.17+68.17%Hold

Adaptive Biotechnologies Stock Forecast FAQ

Is Adaptive Biotechnologies Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ADPT) stock is to Buy ADPT stock.

Out of 5 analysts, 2 (40%) are recommending ADPT as a Strong Buy, 1 (20%) are recommending ADPT as a Buy, 1 (20%) are recommending ADPT as a Hold, 1 (20%) are recommending ADPT as a Sell, and 0 (0%) are recommending ADPT as a Strong Sell.

If you're new to stock investing, here's how to buy Adaptive Biotechnologies stock.

What is ADPT's earnings growth forecast for 2023-2024?

(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 85.06%.

Adaptive Biotechnologies's earnings in 2023 is -$221,496,000.On average, 5 Wall Street analysts forecast ADPT's earnings for 2023 to be -$194,496,534, with the lowest ADPT earnings forecast at -$233,109,816, and the highest ADPT earnings forecast at -$150,162,765.

In 2024, ADPT is forecast to generate -$147,302,522 in earnings, with the lowest earnings forecast at -$165,894,102 and the highest earnings forecast at -$117,269,969.

What is ADPT's revenue growth forecast for 2023-2024?

(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 32.84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 301.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.6%.

Adaptive Biotechnologies's revenue in 2023 is $168,040,000.On average, 5 Wall Street analysts forecast ADPT's revenue for 2023 to be $31,924,889,831, with the lowest ADPT revenue forecast at $31,009,612,027, and the highest ADPT revenue forecast at $33,125,905,926.

In 2024, ADPT is forecast to generate $40,793,073,687 in revenue, with the lowest revenue forecast at $37,318,736,345 and the highest revenue forecast at $42,657,666,190.

What is ADPT's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: ADPT) forecast ROA is -16.66%, which is lower than the forecast US Biotechnology industry average of 1.79%.

What is ADPT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ADPT price target, the average ADPT price target is $16.60, with the highest ADPT stock price forecast at $30.00 and the lowest ADPT stock price forecast at $8.00.

On average, Wall Street analysts predict that Adaptive Biotechnologies's share price could reach $16.60 by Jan 5, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 68.53% from the current ADPT share price of $9.85.

What is ADPT's Earnings Per Share (EPS) forecast for 2023-2024?

(NASDAQ: ADPT) Adaptive Biotechnologies's current Earnings Per Share (EPS) is -$1.57. On average, analysts forecast that ADPT's EPS will be -$1.36 for 2023, with the lowest EPS forecast at -$1.63, and the highest EPS forecast at -$1.05. In 2024, ADPT's EPS is forecast to hit -$1.03 (min: -$1.16, max: -$0.82).

What is ADPT's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: ADPT) forecast ROE is -30.19%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.